Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal Cancer

ISSN： 0735-7907

Source： Cancer Investigation, Vol.29, Iss.7, 2011-07, pp. : 456-459

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 785-789

Spandidos Publications

Access to resources Recommend Favorite

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

By McKeage K. Perry C.M.

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 217-221

Adis International

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia Pronzato Paolo Del Mastro Lucia

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer

By Lidgren Mathias Wilking Nils Jonsson Bengt Rehnberg Clas

Acta Oncologica, Vol. 47, Iss. 6, 2008-08 ,pp. : 1018-1028

Informa Healthcare

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G. Martel C. Lau S. Frankel P. Ruel C. Gu L. Hurria A. Chung C. Luu T. Morgan R. Leong L. Koczywas M. McNamara M. Russell C. Kane S.

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite